Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DN-104
- Development stage
- Preclinical
- Lead developer
- LigaChem Biosciences, Inc.
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DN-104 is a next-generation therapeutic program targeting Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), developed by DAAN Bio Therapeutics. The program utilizes a monoparatopic antibody designed with low affinity for soluble CEACAM5, a strategy intended to minimize off-target sequestration by circulating antigens and enhance tumor-specific localization. DN-104 is being advanced through two distinct therapeutic modalities: an antibody-drug conjugate (ADC) in partnership with LigachemBio (where it is designated as LCB58A) and a CAR-T cell therapy in partnership with GC Cell. Both programs are aimed at treating CEACAM5-positive solid tumors. As of early 2025, both programs have been licensed out, with the ADC program anticipated to reach significant development milestones by approximately 2027.
- Other names
- LCB58ALCB-58ALCB 58A
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on DN-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DN-104.